Date: June 5, 2025
It has come to our attention on the following articles by Business Times:
1) Singapore Paincare worth up to S$0.37 a share, more than double its privatisation offer: Sias by Romaine Chan on 4 June 2025
2) Singapore Paincare up 8.3% on Sias valuation by Therese Soh on 4 June 2025
The above article titles misrepresented SIAS’ position. Our core message was to urge shareholders not to rush into making any decisions and to await the IFA’s report. The referencing to the IPO premium is only meant to illustrate a way for shareholders/IFA to think about fairness given that the company is seeking to delist merely five years after listing at a significant premium to NAV.
For the avoidance of doubt, SIAS did not provide any valuation on the company nor gave financial advice which the article titles will mislead investors to see it that way.
Subscribe to Newsletter
Subscribe to SIAS Mailing List and get updates to all upcoming events and news
By clicking submit, you agree to our privacy statement, collection, use and/or disclosure of your personal data to the extent necessary to provide you with this service.
